טוען...
The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
Over the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada®) is a highly effica...
שמור ב:
| הוצא לאור ב: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7498833/ https://ncbi.nlm.nih.gov/pubmed/32973927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420954119 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|